The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 |
|---|---|
| Revenue | 22,503 |
| Interest income | 27,592 |
| Personnel expense | 40,788 |
| External r&d expense | 85,845 |
| Manufacturing expense | 23,301 |
| Regulatory expense | 3,679 |
| Commercial programs | 19,296 |
| General and administrative expense | 15,374 |
| Depreciation and amortization | 478 |
| Segment adjusted loss before tax | -138,666 |
| Share-based compensation expense | 59,425 |
| Change in fair value - derivatives | 18,783 |
| Foreign exchange gains/(losses) | 13,055 |
| Loss for the year | -203,819 |
| Depreciation and amortization | 220 |
| Fair value change - derivative earnout and warrants | 18,783 |
| Loss on disposal of property, plant and equipment | -12 |
| Foreign exchange (gains)/losses | 13,055 |
| Amortization of premium/discount on available-for-sale debt securities | -1,405 |
| Share-based compensation | 59,425 |
| Changes in prepayments (current and non-current) and other receivables | 13,280 |
| Changes in accounts payable | 4,909 |
| Changes in accrued expenses and other current liabilities | 2,448 |
| Changes in deferred revenue | -2,021 |
| Net cash used in operating activities | -147,783 |
| Purchase of property, plant and equipment, including internal use software | 246 |
| Maturities of marketable securities | 122,063 |
| Purchases of marketable securities | 296,733 |
| Net cash used in investing activities | -174,916 |
| Transaction costs on issue of ordinary shares and pre-funded warrants-December2024Offering | 1,586 |
| Proceeds from exercise of warrants | 1,638 |
| Proceeds from exercise of options | 29,468 |
| Net cash provided by financing activities | 29,520 |
| Net change in cash, cash equivalents and restricted cash | -293,179 |
| Effect of exchange rate changes on cash | 12,759 |
| Cash and cash equivalents at beginning of period | 771,743 |
| Cash and cash equivalents at end of period | 491,323 |
NewAmsterdam Pharma Co N.V. (NAMSW)
NewAmsterdam Pharma Co N.V. (NAMSW)